Altimmune, Inc. (ALT)
Stock Price:
$11.05 USD
-0.34 (-2.99%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $11.10 +0.05 (0.45%) Oct 21, 6:32 PM
Key Info
| Market Cap |
363.68M |
| Revenue (ttm) |
4.15M |
| Net Income (ttm) |
-35.69M |
| Shares Out |
32.91M |
| EPS (ttm) |
-2.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$11.05 |
| Previous Close |
$11.39 |
| Change ($) |
-0.34 |
| Change (%) |
-2.99% |
| Day's Open |
11.25 |
| Day's Range |
10.95 - 11.55 |
| Day's Volume |
826,109 |
| 52-Week Range |
1.51 - 35.10 |
More Stats
| Market Cap |
363.68M |
| Enterprise Value |
284.05M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.91M |
| Float |
30.83M |
| EPS (basic) |
-2.19 |
| EPS (diluted) |
-2.27 |
| FCF / Share |
-0.89 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.08M |
| Short Ratio |
1.33 |
| Short % of Float |
6.76% |
| Beta |
1.51 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
87.55 |
| PB Ratio |
5.37 |
| Revenue |
4.15M |
| Operating Income |
-41.31M |
| Net Income |
-35.69M |
| Free Cash Flow |
-16.00M |
| Net Cash |
79.63M |
| Net Cash / Share |
2.42 |
| Gross Margin |
-271.64% |
| Operating Margin |
-994.44% |
| Profit Margin |
-859.10% |
| FCF Margin |
-385.15% |
| ROA |
-19.75% |
| ROE |
-52.58% |
| ROIC |
-156.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$49.00*
(343.44% upside)
Low
31.0
Current: $11.05
High
80.0
Target: 49.00
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 5.80 | 10.33 | 10.74 | 3.24 | 10.64 | 10.19 | 17.91 | 25.18 | 24.27 | 20.99 |
| Revenue Growth | -43.85% | -3.79% | 231.82% | -69.59% | 4.42% | -43.11% | -28.85% | 3.75% | 15.59% | - |
| Gross Profit | 5.80 | 10.33 | 10.74 | 3.24 | 10.64 | 10.19 | 17.91 | 25.18 | 24.27 | 20.99 |
| Operating Income | -21.46 | -42.83 | -52.05 | -11.09 | -3.40 | -10.19 | -10.84 | -6.27 | -11.73 | -23.55 |
| Net Income | -20.52 | -39.17 | -46.43 | -11.09 | -3.44 | -9.96 | -11.72 | -4.92 | -3.80 | -34.85 |
| Shares Outstanding | 13.12 | 2.80 | 0.43 | 0.23 | 0.21 | 0.19 | 0.17 | 0.16 | 0.16 | 0.11 |
| Earnings Per Share | -1.60 | -15.16 | -118.91 | -49.81 | -15.00 | -51.01 | -69.01 | -30.00 | -24.00 | -324.03 |
| Operating Cash Flow | -9.60 | -9.39 | -20.21 | -6.35 | -3.22 | -8.47 | -7.17 | -2.32 | -7.81 | -14.86 |
| Capital Expenditures | -0.03 | -1.00 | -0.16 | -0.22 | -0.08 | -0.08 | -0.08 | 0.07 | -0.07 | -0.37 |
| Free Cash Flow | -9.63 | -10.39 | -20.37 | -6.57 | -3.29 | -8.56 | -7.25 | -2.26 | -7.88 | -15.24 |
| Cash & Equivalents | 37.27 | 34.35 | 12.30 | 2.88 | 15.57 | 18.64 | 10.48 | 12.70 | 11.34 | 11.89 |
| Total Debt | - | 0.07 | 0.05 | 0.46 | - | 0.75 | 2.82 | 3.78 | 1.89 | 8.36 |
| Net Cash / Debt | 37.27 | 34.28 | 12.25 | 2.42 | 15.57 | 17.90 | 7.66 | 8.92 | 9.45 | 3.52 |
| Assets | 54.06 | 54.75 | 63.03 | 38.40 | 19.86 | 21.98 | 17.14 | 22.74 | 22.80 | 27.20 |
| Liabilities | 8.54 | 6.44 | 14.35 | 6.19 | 3.21 | 3.70 | 9.80 | 11.07 | 6.95 | 14.99 |
| Book Value | 45.52 | 48.31 | 39.40 | 32.21 | 16.65 | 18.27 | 7.34 | 11.67 | 15.85 | 12.21 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Altimmune, Inc. |
| Country |
United States |
| Employees |
25 |
| CEO |
Vipin K. Garg |
Stock Information
| Ticker Symbol |
ALT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ALT |
Description
Altimmune, a clinical stage biopharmaceutical company, focused developing treatments for liver disease, immune modulating therapies, and vaccines. The company develops HepTcell, an immunotherapeutic product candidate that has completed Phase I clinical trial for patients chronically infected with the hepatitis B virus; NasoShield, an anthrax vaccine to provide for protection after a single intranasal administration; NasoVAX, a recombinant intranasal vaccine product candidate; and AdCOVID, a single-dose intranasal vaccine to protect against COVID-19 Its preclinical stage products include ALT-801, a novel peptide-based dual GLP-1/Glucagon receptor agonist for the treatment of non-alcoholic steatohepatitis; and ALT-702, an investigational tumor immunostimulant for treating cancer. The company also develops veterinary product candidates. It has a collaboration with the University of Alabama at Birmingham for the development of AdCOVID. Altimmune, Inc. is headquartered in Gaithersburg, Maryland.